Botulinum Toxin A: Dose-dependent Effect on Reepithelialization and Angiogenesis

Alfred Gugerell, PhD*†, Johanna Kober, PhD*, Melanie Schmid, BSc*, Elisabeth Buchberger, MSc‡, Lars-Peter Kamolz, MD§, Maike Keck, MD*

Background: Botulinum (neuro)toxin A (BoNT) is widely used in the field of plastic and reconstructive surgery. Among treatment of pain, hyperhidrosis, or aesthetic purposes, it is also used to enhance wound healing and prevent excessive scar formation. Some clinical data already exist, but only little is known on a cellular level. The aim of this study was to evaluate the effect of BoNT on cells essential for wound healing in vitro. Therefore, primary human keratinocytes and endothelial cells were treated with different concentrations of BoNT and tested on proliferation, migration, and angiogenic behavior.

Methods: BoNT was exposed to human keratinocytes and endothelial cells in a low (1 IU/mL), medium (10 IU/mL), and high (20 IU/mL) concentrations in cell culture. Proliferation and migration of the 2 cell types were observed and also the angiogenic potential of endothelial cells in vitro.

Results: BoNT 20 IU/mL negatively influenced proliferation and migration of keratinocytes but not those of endothelial cells. Angiogenesis in vitro was less effective with the highest BoNT concentrations tested. Low concentrations of BoNT supported sprouting of endothelial cells.

Conclusions: High concentrations of botulinum toxin interfered with wound closure as keratinocytes’ proliferation and migration were deteriorated. Furthermore, BoNT concentrations of 20 IU/mL constrain in vitro vessel formation but do not influence proliferation or migration of endothelial cells. (Plast Reconstr Surg Glob Open 2016;4:e837; doi: 10.1097/GOX.0000000000000852; Published online 11 August 2016.)

Disclosure: The authors have no financial interest to declare in relation to the content of this article. The Article Processing Charge was paid for by the authors.

Some of the most important cells in wound healing are keratinocytes, responsible for reepithelialization, and endothelial cells, which manage angiogenesis: to close the disrupted epithelial layer, keratinocytes migrate from the wound edge across the wound bed.1 On large-scale burn wounds, coverage with keratinocytes is often achieved by split skin grafts, keratinocyte sheets, or application of keratinocytes with scaffold-like fibrin sealant spray.2 Endothelial cells invade the granulation tissue, form new vessels, and thereby supply the newly formed extracellular matrix with oxygen and nutrients.

Botulinum (neuro)toxin A (BoNT) is a neurotoxin produced by the bacterium Clostridium botulinum, which induces chemodenervation of muscles by preventing the release of neurotransmitters such as acetylcholine and noradrenaline.3 It was primarily found in adulterated meat products by causing botulism. Nowadays, BoNT is commonly used in medical applications to treat chronic myofascial pain,4 headache,5 urinary incontinence,6 and hyperhidrosis7 or in cosmetic applications8,9 among others.

Recently, the effect of botulinum toxin on mature adipocytes, and also adipose-derived stem cells, and fibroblasts was evaluated in vitro.10 Botulinum toxin was shown to have no negative effect on adipose-derived stem cells, mature adipocytes, or fibroblasts. BoNT was also used as an adjuvant in autologous fat transfer in vivo where a higher fat graft survival could be achieved.11 Also, good results in wound healing were reported as BoNT had an effect on the tension in the wound edges with deleterious effects.12 A variety of predominantly clinical studies examined the
impact of BoNT on wound healing, and most of them con-
cluded that an early injection of botulinum toxin type A
seems to enhance healing of facial wounds.13–15

Therefore, we wanted to evaluate the effect of botuli-
num toxin type A (BoNT) on wound healing on a cellular
level. We tested the proliferation and migration of human
keratinocytes and endothelial cells and the angiogenic be-
havior of endothelial cells in vitro.

**MATERIALS AND METHODS**

**Cultivation of Human Umbilical Vein Endothelial Cells and
Keratinocytes**

Human umbilical vein endothelial cells (HUVECs) were
tidly provided by the Cardiac Surgery Research
Laboratories (Dr. Barbara Messner, Medical University of
Vienna, Vienna, Austria). Umbilical cords were kindly do-
nated by the Department of Gynecology, Medical Universi-
ty of Vienna, and isolation of cells is approved by the local
ethics committee (EK number: 1280/2015). All donors
gave written informed consent prior inclusion. Briefly, the
umbilical cord vein was washed using sterile phosphate-
buffered saline (PBS) to remove blood residues and
afterward perfused with collagenase (type IV, 1 mg/mL)
for 20 minutes at room temperature. After rinsing out
the collagenase–endothelial cell suspension with sterile
prewarmed RPMI medium (Lonza; Basel, Switzerland),
HUVECs were collected by centrifugation. Cells were cul-
tured on gelatin-coated (0.2% gelatin) cell culture flasks
and using specialized endothelial cell culture medium
(endothelial growth medium 2 [EGM-2], Lonza). Purity
of cells reached at least 95% (checked by staining with
anti-CD31 antibody and flow cytometry analyses) and was
diluted with the corresponding proliferation medium.

Keratinocytes (Evercyte GmbH; Vienna, Austria) were
cultured in DermaLife K Complete Medium (CellSystems;
Troidorf, Germany). Cells between passages 3 and 8 were
used for experiments.

**Treatment of Cells with BoNT**

Cells were seeded into multiwell plates, depending on
the cell assay. The medium was removed, and cells were in-
cubated with 1-, 10-, and 20-IU/mL onabotulinumtoxin A
(Botox, Allergan Inc.; Irvine, Calif.), respectively. To obtain
different concentrations, a stock solution (200 IU/mL)
was diluted with the corresponding proliferation medium.
As control, cells were incubated with medium only.

**Proliferation**

Keratinocytes and HUVECs were seeded in 96-well plates
(8 × 10^4 cells per well). After 24 hours of cultivation,
medium was changed to BoNT-containing proliferation
medium. As a control, normal proliferation medium with-
out BoNT was added to the cells. The cell number on days
1, 2, and 3 was evaluated using a CellTiter96 nonradio-
active proliferation assay (MTT-Assay, Promega; Madison,
Wis.,) according to the manufacturer’s protocol, and ab-
sorbance was measured on a Wallac 1420 VICTOR2 plate
reader (PerkinElmer; Waltham, Mass.).

**Migration: In Vitro Scratch Assay**

Cells were cultured in 12-well plates until they reached
100% confluence and were then scratched with a 1-mL
plastic micropipette tip. Cells were rinsed with PBS to re-
move detached cells and incubated with BoNT-containing
proliferation medium. Control cells were cultivated in
proliferation medium without BoNT. Cells were analyzed
using an inverted Nikon Eclipse Ti-E microscope (Nikon;
Tokyo, Japan). Wound area was measured with the NIS-
Elements AR 3.0 program (Nikon; Tokyo, Japan) directly
after scratching and after 24, 48, 72, and 118 hours (until
wound closure).

**Angiogenesis: In Vitro Tube-Forming Assay**

Matrigel (basement membrane matrix, growth fac-
tor reduced, BD Biosciences; Bedford, Mass.) was filled
into µ-slide angiogenesis chambers (ibidi; Martinsried,
Germany) and was polymerized for 30 minutes at 37°C.
HUVECs were seeded onto the Matrigel and were incu-
bated with different concentrations of BoNT mixed with
the EGM-2 (Lonza; Basel, Switzerland) containing vascu-
lar endothelial growth factor (VEGF). After 6 hours of in-
cubation, the cells were photographed with an inverted
Nikon Eclipse Ti-E microscope (Nikon; Tokyo, Japan), and
the number of tubes, the total tube length, the num-
ber of loops and branching points, and the covered area
in percent were calculated by Wimasis (Wimasis GmbH;
Munich, Germany).

**Angiogenesis: Spheroid-based In Vitro Sprouting Assay**

Cell spheroids were generated as described by
Korff et al.16 For the sprouting assay, spheroids were
embedded into collagen gels as described in Testori
et al.17 In short, cells were grown overnight in spheroids
in hanging drops containing 0.25% methylocellulose.
Approximately 450 cells formed a spheroid, which was
mixed with rat collagen and 80% of Methocel/20% of
fetal calf serum. The hydrogels with the spheroids were
incubated with different concentrations of BoNT.
Endothelial basal medium 2 (Lonza; Basel, Switzerland)
without supplements was used as negative control, and
medium containing 30-ng/mL VEGF was used as posi-
tive control. After 20 hours of incubation, the cumula-
tive sprout length for each spheroid was calculated with
the cellSens Entry 1.8 program (Olympus Tokyo, Japan).

**Real-time Polymerase Chain Reaction Analysis**

HUVECs were seeded into 6-well plates and incubated
with different concentrations of BoNT mixed with the EGM-2.
Cells with proliferation medium without BoNT were used
as control. After 6 hours of incubation, total RNA was pre-
bared by homogenizing cells in lysis buffer containing 0.1%
2-mercaptoethanol followed by RNA extraction according
to a standard protocol (RNaseasy Mini Kit, Qiagen GmbH;
Hilden, Germany). RNA was transcribed into cDNA by
Quantitect Reverse Transcription Kit (Qiagen). Quantita-
tive real-time polymerase chain reaction (qPCR) was per-
formed using the KAPA SYBR FAST qPCR Kit (peqlab, VWR;
Darmstadt, Germany) with primers for VEGF-A, angiopi-
etin-2 (ANGPT2), and matrix metalloproteinase 9 (MMP9)
normalized to glyceraldehyde 3-phosphate dehydrogenase expression as endogenous control (all Microsynth; Balgach, Switzerland). Expression of specific mRNA in each sample was quantitated in duplicates on an ABI PRISM 7000 Cycler (Applied Biosystems, Foster City, Calif.).

**Statistic**

Statistical analysis was performed with the GraphPad Prism statistic software (GraphPad Software, Inc.; La Jolla, Calif.). Data are presented as mean ± SEM of at least 3 independent experiments. Statistical comparisons were

---

**Fig. 1.** Proliferation of keratinocytes (A) and HUVEC (B) exposed to BoNT after 24, 48, and 72 h. Cell numbers were normalized and related to control (24 h = 100%); n = 3, *P < 0.05 and **P < 0.01.

**Fig. 2.** In vitro wound healing assay of keratinocytes (A and C–E) and HUVECs (B and F–H) exposed to BoNT for 0 h (C and F), 24 h (G), 48 h (D and H), and 72 h (E). Data were normalized and related to baseline (0 h = 100%); n = 3, *P < 0.05; magnification, 40×.
based on paired $t$ test and 1-way analysis of variance followed by Dunnett’s multiple comparison test with $P < 0.05$ considered as significant.

RESULTS

High Concentrations of BoNT Have a Negative Effect on Keratinocytes’ Proliferation and Migration

Proliferation of keratinocytes and HUVECs was observed by measuring the cell number after 24, 48, and 72 hours of incubation with BoNT. Proliferation of keratinocytes was decelerated when incubated with 20 IU/mL BoNT. This effect was significant after 24 and 48 hours but was compensated after 72 hours of cell proliferation (Fig. 1A). In contrast, endothelial cells showed no significant differences in cell proliferation over 3 days (Fig. 1B).

In an in vitro scratch assay, high BoNT concentrations of 20 IU/mL had a negative effect on keratinocytes’ migration as the scratch is closed significantly slower compared with the medium control (Fig. 2A). No significant effect could be observed with HUVECs (Fig. 2B).

High Concentrations of BoNT Have a Negative Effect on Neoangiogenesis

HUVECs were seeded in a basal membrane and incubated with different concentrations of BoNT (Fig. 3). Compared with medium control, HUVEC built significantly fewer tubes when incubated with 20-IU/mL BoNT. Also the total tube length was less with the highest BoNT concentration tested (Fig. 4A, B). Significant differences could also be shown in the quality of the tubes: both the number of built vessel loops and the branching points between the vessels were fewer with 20-IU/mL BoNT compared with the control (Fig. 4C, D). Concerning the cell-covered area, no differences between the samples could be observed.

In sprouting assay experiments, cell spheroids were encapsulated into a hydrogel and had to migrate and invade into the surrounding to build vessel-like structures. Compared with the negative control, low BoNT concentrations of 1 and 10 IU/mL enhanced sprouting of endothelial cells, and more vessels were formed. Spheroids treated with 20-IU/mL BoNT did not build more sprouts than the negative control (Fig. 5).

Real-time PCR analysis showed significantly lower expressions of VEGF-A, ANGPT2, and MMP9 in higher BoNT levels (Fig. 6).

DISCUSSION

A variety of studies show that botulinum toxin type A injections induce temporary muscular paralysis and relieve the tension on wound edges. This relief of tension may help prevent the widening, hypertrophy, and hyperpigmentation of facial scars. Only few studies...
have been conducted that investigate the biological effects of BoNT in terms of wound healing beyond the effect of immobilization. However, it has been shown that BoNT inhibits fibroblast proliferation and in addition promotes apoptosis of fibroblasts derived from hypertrophic scars. BoNT has also been reported to reduce the expression of transforming growth factor beta-1. Therefore, it has even been suggested that BoNT might be used to decrease fibrosis. Clinical results suggest that it would benefit in early stages of scar formation when fibroblasts have stronger proliferative and apoptotic activity.

In our present study, we focused on the behavior of keratinocytes and endothelial cells under the influence of BoNT in different concentrations to observe its impact on wound healing. An in vitro scratch assay imitates wounding in vivo by damaging a confluent cell layer and destruct cell–cell contact. Therefore, cell migration is triggered. We were able to show that in the highest concentration of 20 IU/mL, BoNT had a diminishing effect on keratinocyte migration and proliferation. Lower concentrations of BoNT did not show such an effect. Therefore, a low BoNT concentration is suggested to be used for fast reepithelialization.

In several in vivo studies, it was shown that BoNT increases blood supply, which accelerates the process of healing and prevents the collapse of the peripheral vessels in the cutaneous flap. Additionally, increased diameters of arterioles and venules were observed histologically.

In our study, we observed the effect of BoNT on a cellular basis. We used tube-forming assays and spheroid-sprouting assays to evaluate the impact of different concentrations of BoNT on angiogenesis. We were able to detect reduced vessel formation with endothelial cells in vitro in the tube-forming assay with high BoNT concentrations of 20 IU/mL. The tube formation assay is one of the
most widely used in vitro assays to model the early stages of angiogenesis. Endothelial cells were plated on a hydrogel of basement matrix, which supports the cells to form capillary-like structures. Tube formation is typically quantified by measuring the number, length, complexity, or area of these structures. The assay can be used to identify inhibitors or stimulators of angiogenesis. This assay involves endothelial cell adhesion, migration, protease activity, and tubule formation. In gene expression level, endothelial cells had a significantly reduced VEGF-A and ANGPT2 expression after 6 hours when incubated with high BoNT concentrations. This indicates a reduced potency for neoangiogenesis. Furthermore, a sprouting assay can identify proangiogenic and antiangiogenic effects of test substances. The assay simulates the entire angiogenesis process in vitro in 3 dimensions: proliferation, invasion, migration, and proteolytic activity of endothelial cells. In contrast to the tube formation assay, also three-dimensional networks can be observed. The number and length of the sprouts correspond with the pro- or antiangiogenicity of the test substance. Again, in our experimental setting, we were able to observe an inhibition of angiogenesis when spheroids were treated with high BoNT concentrations of 20 IU/mL for 6 hours (Fig. 6). Low concentrations of 1 and 10 IU/mL enhanced sprouting of endothelial cells with more vessels being formed compared with the negative control. In contrast, no influence of BoNT on proliferation or migration of endothelial cells could be observed.

As already discussed in a previous study, a wide range of concentrations of BoNT is used in the clinical settings. In the literature, concentrations between 1 and 10 IU/mL were used; according to the package inserts, a dose of 5 IU per injection for overactive bladder, 1.25 to 2.5 units per injection for blepharospasm or strabismus (Botox), and 4 IU per intramuscular injection (Botox Cosmetic, Allergan Inc., Irvine, Calif.) are recommended. Furthermore, medical use generally involves significantly higher doses than cosmetic treatment. Therefore, we tested 1 and 10 units per mL, and also 20 IU as a high dose of BoNT.

Chang et al. revealed that several clinical studies showed that BoNT can improve facial scars, but so far no proven explanation for the benefit of BoNT on a cellular level could be provided.

In this study, we showed an important effect of BoNT on cells important for wound healing: High doses of BoNT (20 IU/mL) had a diminishing effect on wound closure by decelerating proliferation and migration of keratinocytes, thereby inhibiting reepithelialization. Additionally, those high concentrations diminished angiogenesis by showing a negative effect on vessel formation by endothelial cells.

**REFERENCES**

1. Grose R, Hutter C, Bloch W, et al. A crucial role of beta 1 integrins for keratinocyte migration in vitro and during cutaneous wound repair. *Development* 2002;129:2303–2315.
2. Currie LJ, Sharpe JR, Martin R. The use of fibrin glue in skin grafts and tissue-engineered skin replacements: a review. *Plast Reconsr Surg*. 2001;108:1713–1726.
3. Burgen ASV, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. *J Physiol*. 1949;109:10–24.
4. Nix WA. Botulinum toxin in chronic myofascial pain. *Schmerz*. 2007;21:467–468.
5. Ashkenazi A, Silberstein S. Botulinum toxin type A for the treatment of headache: why we say yes. *Arch Neurol*. 2008;65:146–149.
6. Santos-Silva A, da Silva CM, Cruz F. Botulinum toxin treatment for bladder dysfunction. *Int J Urol*. 2013;20:599–609.
7. Wheeler T. Sweat and tears: treating the patient with primary hyperhidrosis. *Br J Nurs*. 2012;21:408, 410–412.
8. Beer K, Wäibel J. Botulinum toxin type A enhances the outcome of fractional resurfacing of the cheek. *J Drugs Dermatol*. 2007;6:1151–1152.
9. Lee H, Saladi RN, Fox JL. Cohort study on patient response to botulinum toxin cosmetic therapy. *J Cosmet Dermatol*. 2008;7:130–142.
10. Gugerell A, Kober J, Schmid M, et al. Botulinum toxin A and lidocaine have an impact on adipose-derived stem cells, fibro-
blasts, and mature adipocytes in vitro. *J Plast Reconstr Aesthet Surg*. 2014;67:1276–1281.

11. Baek RM, Park SO, Jeong EC, et al. The effect of botulinum toxin A on fat graft survival. *Aesthetic Plast Surg*. 2012;36:680–686.

12. Al-Qattan MM, Al-Shanawani BN, Alshomer F. Botulinum toxin type A: implications in wound healing, facial cutaneous scarring, and cleft lip repair. *Ann Saudi Med*. 2013;33:482–488.

13. Ziade M, Domergue S, Batifol D, et al. Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomised study. *J Plast Reconstr Aesthet Surg*. 2013;66:209–214.

14. Wilson AM. Use of botulinum toxin type A to prevent widening of facial scars. *Plast Reconstr Surg*. 2006;117:1758–1766; discussion 1767–1768.

15. Tollefson TT, Senders CM, Sykes JM, et al. Botulinum toxin to improve results in cleft lip repair. *Arch Facial Plast Surg*. 2006;8:221–222.

16. Korff T, Krauss T, Augustin HG. Three-dimensional spheroidal culture of cytotrophoblast cells mimics the phenotype and differentiation of cytotrophoblasts from normal and preeclamptic pregnancies. *Exp Cell Res*. 2004;297:415–423.

17. Testori J, Schweighofer B, Helfrich I, et al. The VEGF-regulated transcription factor HLX controls the expression of guidance cues and negatively regulates sprouting of endothelial cells. *Blood*. 2011;117:2735–2744.

18. Zhibo X, Miao Z. Botulinum toxin type A affects cell cycle distribution of fibroblasts derived from hypertrophic scar. *J Plast Reconstr Aesthet Surg*. 2008;61:1128–1129.

19. Xiao Z, Zhang F, Lin W, et al. Effect of botulinum toxin type A on transforming growth factor beta1 in fibroblasts derived from hypertrophic scar: a preliminary report. *Aesthetic Plast Surg*. 2010;34:424–427.

20. Aydin A, Memisoglu K, Cengiz A, et al. Effects of botulinum toxin A on fracture healing in rats: an experimental study. *J Orthop Sci*. 2012;17:796–801.

21. Kim YS, Roh TS, Lee WJ, et al. The effect of botulinum toxin A on skin flap survival in rats. *Wound Repair Regen*. 2009;17:411–417.

22. Staton CA, Reed MW, Brown NJ. A critical analysis of current in vitro and in vivo angiogenesis assays. *Int J Exp Pathol*. 2009;90:195–221.

23. Arnaoutova I, Kleinman HK. In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. *Nat Protoc*. 2010;5:628–635.

24. Haubner F, Leyh M, Ohmann E, Sadick H, Gassner HG. Effects of botulinum toxin A on patient-specific keloid fibroblasts in vitro. *The Laryngoscope* 2014;124:1344–1351.

25. Jung MK, Song SB, Cheon SY, et al. Botulinum toxin enhances the implantation effect of adipocytes in C57/BL6 mice. *Aesthetic Plast Surg*. 2009;33:722–729.

26. Bagheri M, Jahromi BM, Bagheri M, et al. A pilot study on lipo-lytic effect of subcutaneous botulinum toxin injection in rabbits. *Anal Quant Cytol Histol*. 2010;32:186–191.

27. Allergan, I. BOTOX® Product Information. 2013. Available at: http://www.allergan.com/assets/pdf/botox_pi.pdf.

28. Allergan, I. BOTOX® Cosmetic Product Information. 2013. Available at: http://www.allergan.com/assets/pdf/botox_cosmetic_pi.pdf.

29. Berry MG, Stanek JJ. Botulinum neurotoxin A: a review. *J Plast Reconstr Aesthet Surg*. 2012;65:1283–1291.

30. Chang C-S, Wallace CG, Hsiao Y-C, Chang C-J, Chen PK-T. Botulinum toxin to improve results in cleft lip repair: a double-blinded, randomized, vehicle-controlled clinical trial. *PLoS ONE*. 2014;9(12):e115690. doi:10.1371/journal.pone.0115690.

31. Gassner HG, Brissett AE, Otley CC, et al. Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. *Mayo Clin Proc*. 2006;81:1023–1028.

32. Flynn TC. Use of intraoperative botulinum toxin in facial reconstruction. *Dermatol Surg*. 2009;35:182–188.